Olomax (amlodipine/olmesartan/rosuvastatin) / Daewoong Pharma - LARVOL DELTA

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia (clinicaltrials.gov) - P=N/A | N=4000 | Active, not recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Trial completion date: Jun 2025 ➔ Dec 2025

Real-world evidence • Trial completion date • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia (clinicaltrials.gov) - P=N/A | N=4000 | Active, not recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Apr 2025 | Trial primary completion date: Apr 2024 ➔ Nov 2024

Enrollment closed • Real-world • Real-world evidence • Trial completion date • Trial primary completion date • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab (clinicaltrials.gov) - P=N/A | N=5450 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Enrolling by invitation ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia (clinicaltrials.gov) - P=N/A | N=4000 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Trial completion date: Dec 2023 ➔ Oct 2024 | Trial primary completion date: Mar 2023 ➔ Apr 2024

Real-world • Real-world evidence • Trial completion date • Trial primary completion date • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia (clinicaltrials.gov) - P=N/A | N=4000 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.

New trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease (clinicaltrials.gov) - P4 | N=106 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Recruiting ➔ Completed | N=198 ➔ 106 | Trial completion date: Feb 2020 ➔ Jul 2021 | Trial primary completion date: Feb 2020 ➔ Jul 2021

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia (clinicaltrials.gov) - P3; N=265; Completed; Sponsor: Daewoong Pharmaceutical Co. LTD.; Recruiting ➔ Completed; N=102 ➔ 265

Clinical • Enrollment change • Trial completion • Dyslipidemia • Hypertension

Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab (clinicaltrials.gov) - P=N/A; N=7000; Enrolling by invitation; Sponsor: Daewoong Pharmaceutical Co. LTD.

Clinical • New trial • Dyslipidemia • Hypertension • Metabolic Disorders • CRP